Imatron Announces First Ultrafast CT Scanner Sale in South America; Hospital Israelita Albert Einstein in Sao Paulo, Brazil.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 30, 1998-- Imatron Inc. (Nasdaq:IMAT) announced today that it has sold an Ultrafast CT(R) scanner to the Hospital Israelita Albert Einstein in Sao Paulo, Brazil. Shipment of Imatron's Ultrafast CT scanner will be recognized as a sale in the company's fourth fiscal quarter.

Hospital Israelita Albert Einstein is a philanthropic 500-bed hospital, founded and supported by the local Jewish Community, being recognized as one of the leading institutions in Brazil for its excellence in health care delivery.

Dr. Jairo Tabacow Hidal, Vice President for Medical Practice, said, "As one of the premier medical facilities in Sao Paulo, we are pleased to bring Imatron's Ultrafast CT scanner to the Hospital Israelita Albert Einstein. The Hospital endorses a preventive approach to healthcare and believes in the life saving benefits of early detection and diagnosis of cardiovascular disease. We look forward to utilizing Imatron's revolutionary technology in our preventive medical programs and to further advancing the use of EBT technology."

S. Lewis Meyer, Imatron's President and CEO, said, "This sale of Imatron's Ultrafast CT scanner to the Albert Einstein Jewish Hospital in Sao Paulo validates our strategy of developing major international markets. With our opening of this new market, Imatron's Ultrafast CT coronary artery scan will now be made available to the 6th populous country in the world. Sao Paulo, the designated site of our first Ultrafast CT scanner in Brazil, is one of the world's largest cities and the largest city in South America with a population of more than 18 million people. We are confident that introducing Ultrafast CT to Brazil with the support and endorsement of the Albert Einstein Jewish Hospital will lead to future sales in this important market. We are optimistic that this sale is an indication that the international economic uncertainty affecting many countries may be waning, setting the stage for increased international sales."

Imatron, Inc. is primarily engaged in designing, manufacturing, marketing, and supporting high performance computed tomography (CT) scanners based on the Company's proprietary scanning electron beam technology. Ultrafast CT is a registered trademark of Imatron. Imatron's Ultrafast CT scanner is now in use at major medical centers around the world, including The Mayo Clinic, University of Iowa, National Institutes of Health, UCLA, Stanford University, University of Illinois, The Arizona Heart Institute, The Royal Brompton Hospital in London, Tokyo University Hospital and Beijing Hospital.

Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements that are based on current expectations and estimates about the industry in which Imatron operates, the estimated impact of certain technological advances, the estimated impact of published research studies on scanner sales and procedures, as well as management's beliefs and assumptions. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. The factors that could cause actual results to differ materially include, among others: failed clinical demonstration of certain asserted technological advantages and diagnostic capabilities; reliance on product distributors; competition in the diagnostic imaging market; failure to improve product reliability or introduce new product models and enhancements; delays in production and difficulty in obtaining components and sub-assemblies from limited sources of supply; inability to meet cash-on-delivery or prepayment terms from vendors; determinations by regulatory and administrative government authorities; patent expiration and denial of patent applications; the high cost of the scanner as compared to commercially available CT scanners; and the risk factors listed from time to time in the Company's Securities and Exchange Commission reports, including their reports on Form 10-K for their current fiscal year.